Article
Multidisciplinary Sciences
Lisa Schulz, Sarah Werner, Julia Boettner, Volker Adams, Philipp Lurz, Christian Besler, Holger Thiele, Petra Buettner
Summary: Diastolic dysfunction in HFpEF is associated with alterations in the cardiac microtubule network, including increased concentration and detyrosination levels of alpha-tubulin. The decreased tyrosination/alpha-tubulin ratio suggests potential contributions to diastolic dysfunction in HFpEF and highlights MT homeostasis as a new target for pharmacological interventions.
SCIENTIFIC REPORTS
(2022)
Article
Cardiac & Cardiovascular Systems
Maria Valero-Munoz, Eng Leng Saw, Ryan M. M. Hekman, Benjamin C. C. Blum, Zaynab Hourani, Henk Granzier, Andrew Emili, Flora Sam
Summary: This study identifies the cardiac-specific features of protein and phosphoprotein changes in a murine model of heart failure with preserved ejection fraction (HFpEF). The findings highlight significant changes in proteins related to mitochondrial metabolism and the cardiac contractile apparatus, suggesting a potential role for SIRT3 in perpetuating these changes and as a target for drug development in HFpEF.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Letter
Medicine, General & Internal
Elric Zweck, Ralf Westenfeld, Bjorn Redfors, Elmir Omerovic, Robin A. P. Weir, Domenico Gabrielli, Fabrizio Oliva, Giuseppe Zuccala, Scott D. Solomon, Muthiah Vaduganathan, John J. V. McMurray
Summary: Solomon et al. report on the DELIVER trial, which showed that dapagliflozin reduced risks of heart failure-related outcomes in patients with a mildly reduced or preserved left ventricular ejection fraction. These findings are expected to influence guidelines and clinical practice. The trial also confirmed dapagliflozin's efficacy in patients with a left ventricular ejection fraction of 60% or above.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Letter
Medicine, General & Internal
Debdatta Bhattacharyya, Ayan Kar, Saurabh Dhumale, Filippos K. Triposkiadis, Andrew Xanthopoulos, Efstathios K. Iliodromitis, James Amato, Hiddo J. L. Heerspink, Lesley Inker, Tom Greene, Stefan D. Anker, Javed Butler, Milton Packer
Summary: In patients with heart failure and preserved ejection fraction, Empagliflozin reduced the incidence of primary outcome events compared to other drugs, but had higher rates of cardiovascular death, death from any cause, and hospitalization for heart failure compared to spironolactone.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Physiology
Shyam S. Nandi, Kenichi Katsurada, Michael J. Moulton, Hong Zheng, Kaushik P. Patel
Summary: This study suggests that enhanced central sympathetic drive may contribute to the development of heart failure with preserved ejection fraction (HFpEF). Rats infused with angiotensin II exhibited diastolic dysfunction, cardiac hypertrophy, and fibrosis. These findings provide insights into the underlying mechanisms of HFpEF and establish a new animal model for further research.
FRONTIERS IN PHYSIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Sebastian Rosch, Karl-Patrik Kresoja, Christian Besler, Karl Fengler, Anne Rebecca Schoeber, Maximilian von Roeder, Christian Luecke, Matthias Gutberlet, Karin Klingel, Holger Thiele, Karl-Philipp Rommel, Philipp Lurz
Summary: In this study, patients with heart failure with preserved ejection fraction (HFpEF) were stratified based on left ventricular ejection fraction (LVEF), resulting in distinct morphologic and pathophysiologic subphenotypes. Patients with LVEF ranging from 50% to 60% demonstrated reduced contractility, impaired ventriculo-arterial coupling, and higher extracellular volume fraction, while patients with LVEF >60% exhibited a hypercontractile state with excessive left ventricular afterload and diminished preload reserve.
Article
Cardiac & Cardiovascular Systems
Soeren J. Backhaus, Torben Lange, Elisabeth F. George, Kristian Hellenkamp, Roman J. Gertz, Marcus Billing, Rolf Wachter, Michael Steinmetz, Shelby Kutty, Uwe Raaz, Joachim Lotz, Tim Friede, Martin Uecker, Gerd Hasenfuss, Tim Seidler, Andreas Schuster
Summary: Real-time cardiac magnetic resonance (RT-CMR) exercise imaging can accurately diagnose HFpEF, providing a suitable noninvasive diagnostic alternative, which may be beneficial for routine clinical use pending further multicenter studies.
Article
Cardiac & Cardiovascular Systems
Barry A. Borlaug, Kavita Sharma, Sanjiv J. Shah, Jennifer E. Ho
Summary: The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing due to aging, obesity, sedentariness, and cardiometabolic disorders. Despite recent advances in understanding its pathophysiological effects and introduction of new diagnosis approaches, HFpEF remains under-recognized. This is concerning as effective treatments have been identified. This article provides an in-depth examination of the epidemiology, pathophysiology, diagnosis, and treatment of HFpEF. (J Am Coll Cardiol 2023;81:1810-1834) (c) 2023 by the American College of Cardiology Foundation.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Multidisciplinary Sciences
Ravi B. Patel, Carolyn S. P. Lam, Sara Svedlund, Antti Saraste, Camilla Hage, Ru-San Tan, Lauren Beussink-Nelson, Jasper Tromp, Cynthia Sanchez, Joyce Njoroge, Stanley A. Swat, Ulrika Ljung Faxen, Maria Lagerstrom Fermer, Ashwin Venkateshvaran, Li-Ming Gan, Lars H. Lund, Sanjiv J. Shah
Summary: In HFpEF, disproportionate LA myopathy may indicate better LV diastolic function but is associated with lower stroke volume reserve after passive leg raise independent of AF. Additionally, disproportionate LA myopathy is linked to higher pulmonary artery systolic pressure, higher pulmonary vascular resistance, and lower coronary flow reserve.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Bolrathanak Oeun, Shungo Hikoso, Daisaku Nakatani, Hiroya Mizuno, Shinichiro Suna, Tetsuhisa Kitamura, Katsuki Okada, Tomoharu Dohi, Yohei Sotomi, Hirota Kida, Akihiro Sunaga, Taiki Sato, Akito Nakagawa, Yusuke Nakagawa, Takaharu Hayashi, Masamichi Yano, Shunsuke Tamaki, Yoshio Yasumura, Takahisa Yamada, Yasushi Sakata
Summary: The semiquantitative urine dipstick test may serve as a prognostic marker in patients with HFpEF, indicating its potential usefulness for risk stratification in this population.
Article
Cardiac & Cardiovascular Systems
Dan Tong, Gabriele G. Schiattarella, Nan Jiang, Francisco Altamirano, Pamela A. Szweda, Abdallah Elnwasany, Dong I. Lee, Heesoo Yoo, David A. Kass, Luke I. Szweda, Sergio Lavandero, Eric Verdin, Thomas G. Gillette, Joseph A. Hill
Summary: The study demonstrated through a mouse model that HFpEF is associated with myocardial mitochondrial dysfunction, and NAD(+) supplementation is considered a promising therapeutic approach.
CIRCULATION RESEARCH
(2021)
Article
Cardiac & Cardiovascular Systems
Joban Vaishnav, Lisa R. Yanek, Virginia S. Hahn, Eunice Yang, Rishi Trivedi, David A. Kass, Kavita Sharma
Summary: This study evaluated whether HFpEF patients with hemodynamic evidence met the inclusion criteria for major HFpEF clinical trials and compared the clinical characteristics and cardiovascular outcomes between patients who met and did not meet the criteria. The study found that only a small proportion of patients met the inclusion criteria and there was no difference in outcomes between patients who did or did not meet the criteria.
JOURNAL OF CARDIAC FAILURE
(2022)
Article
Cardiac & Cardiovascular Systems
Javed Butler, Gerasimos Filippatos, Tariq Jamal Siddiqi, Martina Brueckmann, Michael Bohm, Vijay K. Chopra, Joao Pedro Ferreira, James L. Januzzi, Sanjay Kaul, Ileana L. Pina, Piotr Ponikowski, Sanjiv J. Shah, Michele Senni, Ola Vedin, Subodh Verma, Barbara Peil, Stuart J. Pocock, Faiez Zannad, Milton Packer, Stefan D. Anker
Summary: This study evaluated the impact of Empagliflozin on health-related quality of life in patients with heart failure and preserved ejection fraction. The results showed that Empagliflozin reduced the risk of major heart failure outcomes and improved health-related quality of life. The effects were consistent across different levels of baseline health status.
Review
Cell Biology
Miyesaier Abudureyimu, Xuanming Luo, Xiang Wang, James R. Sowers, Wenshuo Wang, Junbo Ge, Jun Ren, Yingmei Zhang
Summary: Type 2 diabetes mellitus (T2DM) is associated with a high incidence of heart failure (HF), leading to poor prognosis. HF in T2DM is characterized by cardiovascular geometry and function abnormalities, which are closely related to metabolic syndrome.
JOURNAL OF MOLECULAR CELL BIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Thassio Mesquita, Rui Zhang, Jae Hyung Cho, Rui Zhang, Yen-Nien Lin, Lizbeth Sanchez, Joshua Goldhaber, Joseph K. Yu, Jialiu A. Liang, Weixin Liu, Natalia A. Trayanova, Eugenio Cingolani
Summary: Chronotropic incompetence and sinoatrial node (SAN) dysfunction are common problems in patients with heart failure, but the underlying mechanisms are not yet fully understood. This study identified intrinsic abnormalities in SAN structure and function as the cause of chronotropic incompetence in heart failure patients with preserved ejection fraction (HFpEF).
Article
Cardiac & Cardiovascular Systems
Scott D. Solomon, Brian L. Claggett, Zi Michael Miao, Rafael Diaz, G. Michael Felker, John J. McMurray, Marco Metra, Ramon Corbalan, Gerasimos Filippatos, Assen R. Goudev, Viatcheslav Mareev, Pranas Serpytis, Thomas Suter, Mehmet B. Yilmaz, Faiez Zannad, Stuart Kupfer, Stephen B. Heitner, Fady Malik, John R. Teerlink
Summary: In the GALACTIC-HF study, the influence of atrial fibrillation on the effectiveness of omecamtiv mecarbil was explored. The study found that patients with atrial fibrillation derived less benefit from omecamtiv mecarbil treatment, especially those who were also receiving digoxin.
EUROPEAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Eva M. Boorsma, Jozine M. Ter Maaten, Kevin Damman, Bart J. van Essen, Faiez Zannad, Dirk J. van Veldhuisen, Nilesh J. Samani, Kenneth Dickstein, Marco Metra, Gerasimos Filippatos, Chim C. Lang, Leong Ng, Stefan D. Anker, John G. Cleland, Pierpaolo Pellicori, Ron T. Gansevoort, Hiddo J. L. Heerspink, Adriaan A. Voors, Johanna E. Emmens
Summary: Albuminuria is common in patients with heart failure and is associated with clinical symptoms and biomarkers of congestion. It is also related to the severity and prognosis of heart failure.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Mauro Riccardi, Daniela Tomasoni, Enrico Vizzardi, Marco Metra, Marianna Adamo
Summary: Heart failure with preserved ejection fraction (HFpEF) is a common form of heart failure that requires effective management. This review examines the use of percutaneous interatrial shunting devices in HFpEF patients, finding that these devices are safe and effective in improving hemodynamic and clinical parameters. However, data on cardiovascular mortality and re-hospitalization are limited.
HEART FAILURE REVIEWS
(2023)
Review
Cardiac & Cardiovascular Systems
Antonio Sisinni, Maurizio Taramasso, Fabien Praz, Marco Metra, Eustachio Agricola, Alberto Margonato, Neil Fam, Rodrigo Estevez-Loureiro, Azeem Latib, David Messika-Zeitoun, Lenard Conradi, Ralph Stephan von Bardeleben, Paul Sorajja, Rebecca T. Hahn, Sergio Caravita, Francesco Maisano, Marianna Adamo, Cosmo Godino
Summary: Secondary tricuspid regurgitation is common in patients with mitral regurgitation. It is important to offer adequate treatment to patients with combined valvular heart disease in order to improve long-term survival. However, there is currently no conclusive data on the prognostic impact of concomitant tricuspid valve surgery during mitral valve surgery. Transcatheter treatments provide new opportunities for simultaneous or stepwise treatment of both conditions.
JACC-CARDIOVASCULAR INTERVENTIONS
(2023)
Article
Cardiac & Cardiovascular Systems
George Markousis-Mavrogenis, Waldemar B. Minich, Ali A. Al-Mubarak, Stefan D. Anker, John G. F. Cleland, Kenneth Dickstein, Chim C. Lang, Leong L. Ng, Nilesh J. Samani, Faiez Zannad, Marco Metra, Petra Seemann, Antonia Hoeg, Patricio Lopez, Dirk J. van Veldhuisen, Rudolf A. de Boer, Adriaan A. Voors, Peter van der Meer, Lutz Schomburg, Nils Bomer
Summary: The study examined the importance of autoantibodies against adrenergic/muscarinic receptors in heart failure. The findings suggest that anti-beta 1 AABs are independently associated with HF rehospitalization, while other AABs are mainly related to comorbidities and medication use.
CARDIOVASCULAR RESEARCH
(2023)
Letter
Cardiac & Cardiovascular Systems
Subodh Verma, Deepak L. Bhatt, Nitish K. Dhingra, Gabriel Steg, Michael Szarek, Michael Davies, Marco Metra, Lars H. Lund, Bertram Pitt, S. O. L. O. I. S. T. Investigators SOLOIST Investigators
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Matteo Pagnesi, Marco Metra, Alain Cohen-Solal, Christopher Edwards, Marianna Adamo, Daniela Tomasoni, Carolyn S. P. Lam, Ovidiu Chioncel, Rafael Diaz, Gerasimos Filippatos, Piotr Ponikowski, Karen Sliwa, Adriaan A. Voors, Antoine Kimmoun, Maria Novosadova, Koji Takagi, Marianela Barros, Albertino Damasceno, Hadiza Saidu, Etienne Gayat, Peter S. Pang, Jelena Celutkiene, Gad Cotter, Alexandre Mebazaa, Beth Davison
Summary: This study demonstrates that a strategy of rapid uptitration of oral treatment for heart failure and close follow-up, compared with usual care, can significantly improve the prognosis of patients with acute heart failure, regardless of left ventricular ejection fraction. This approach reduces the risk of HF rehospitalization or all-cause death within 180 days after AHF hospitalization, independently of LVEF.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Theresa A. McDonagh, Marco Metra, Marianna Adamo, Roy S. Gardner, Andreas Baumbach, Michael Boehm, Haran Burri, Javed Butler, Jelena Celutkiene, Ovidiu Chioncel, John G. F. Cleland, Maria Generosa Crespo-Leiro, Dimitrios Farmakis, Martine Gilard, Stephane Heymans, Arno W. Hoes, Tiny Jaarsma, Ewa A. Jankowska, Mitja Lainscak, Carolyn S. P. Lam, Alexander R. Lyon, John J. V. McMurray, Alexandre Mebazaa, Richard Mindham, Claudio Muneretto, Massimo Francesco Piepoli, Susanna Price, Giuseppe M. C. Rosano, Frank Ruschitzka, Anne Kathrine Skibelund
EUROPEAN HEART JOURNAL
(2023)
Review
Cardiac & Cardiovascular Systems
Marija Polovina, Carsten Tschoepe, Giuseppe Rosano, Marco Metra, Filippo Crea, Wilfried Mullens, Johann Bauersachs, Karen Sliwa, Rudolf A. de Boer, Dimitrios Farmakis, Thomas Thum, Domenico Corrado, Antoni Bayes-Genis, Biykem Bozkurt, Gerasimos Filippatos, Andre Keren, Hadi Skouri, Brenda Moura, Maurizio Volterrani, Magdy Abdelhamid, Milika Asanin, Gordana Krljanac, Milenko Tomic, Gianluigi Savarese, Marianna Adamo, Yuri Lopatin, Ovidiu Chioncel, Andrew J. S. Coats, Petar M. Seferovic
Summary: Cardiomyopathies contribute significantly to cardiovascular morbidity and mortality, with heart failure and sudden cardiac death (SCD) being the main concerns. The risk of SCD is influenced by various factors such as etiology, genetics, age, sex, physical exertion, and disease severity. This review provides an in-depth discussion on the burden, risk assessment, and prevention of SCD in different types of cardiomyopathies. It highlights the need for further research in certain areas to improve SCD prevention strategies.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Daniela Tomasoni, Marianna Adamo, Aldostefano Porcari, Alberto Aimo, Giovanni Battista Bonfioli, Vincenzo Castiglione, Maria Franzini, Riccardo Maria Inciardi, Anas Khalil, Carlo Mario Lombardi, Laura Lupi, Matilde Nardi, Chiara Oriecuia, Matteo Pagnesi, Giorgia Panichella, Maddalena Rossi, Nicola Saccani, Claudia Specchia, Giuseppe Vergaro, Marco Merlo, Gianfranco Sinagra, Michele Emdin, Marco Metra
Summary: The prognostic value of the right ventricle-to-pulmonary artery (RV-PA) coupling was investigated in patients with either transthyretin (ATTR) or immunoglobulin light-chain (AL) cardiac amyloidosis (CA). The study found that the TAPSE/PASP ratio predicted the risk of mortality or heart failure hospitalization in CA patients. The TAPSE/PASP ratio was more effective in predicting prognosis compared to TAPSE or PASP alone.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING
(2023)
Article
Cardiac & Cardiovascular Systems
Bertram Pitt, Deepak L. Bhatt, Michael Szarek, Christopher P. Cannon, Lawrence A. Leiter, Darren K. Mcguire, Julia B. Lewis, Matthew C. Riddle, Adriaan A. Voors, Marco Metra, Lars H. Lund, Michel Komajda, Jeffrey M. Testani, Christopher S. Wilcox, Piotr Ponikowski, Renato D. Lopes, Justin A. Ezekowitz, Franklin Sun, Michael J. Davies, Subodh Verma, Mikhail N. Kosiborod, SOLOIST WHF Investigators
Summary: The study finds that starting sotagliflozin before discharge in type 2 diabetes patients hospitalized for WHF can significantly decrease cardiovascular deaths and HF events through 30 and 90 days after discharge. However, sotagliflozin may have slightly higher rates of diarrhea and volume-related events compared to placebo.
JACC-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Mauro Riccardi, Antonio M. Sammartino, Marianna Adamo, Riccardo M. Inciardi, Carlo M. Lombardi, Nicola R. Pugliese, Daniela Tomasoni, Enrico Vizzardi, Marco Metra, Andrew J. S. Coats, Matteo Pagnesi
Summary: Heart failure with preserved ejection fraction (HFpEF) is associated with functional limitations, poor quality of life, and increased mortality, yet there are no effective device-based therapies available. Cardiac contractility modulation (CCM) therapy, which applies extracellular electrical stimulation to myocytes during the absolute refractory period, has shown potential benefits in patients with HFpEF and improvements in terms of symptoms and quality of life. However, large prospective studies are needed to further evaluate the safety and efficacy of CCM in HFpEF patients.
HEART FAILURE REVIEWS
(2023)
Review
Cardiac & Cardiovascular Systems
Giuliana Cimino, Muthiah Vaduganathan, Carlo M. Lombardi, Matteo Pagnesi, Enrico Vizzardi, Daniela Tomasoni, Marianna Adamo, Marco Metra, Riccardo M. Inciardi
Summary: Recent studies have shown the potential beneficial role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of HFpEF patients with obesity. These drugs regulate signaling pathways within the gastrointestinal tract, pancreas, and central nervous system to delay gastric emptying, decrease appetite, increase insulin secretion, and suppress glucagon release.
Review
Cardiac & Cardiovascular Systems
Chiara Oriecuia, Daniela Tomasoni, Isabella Sala, Giovanni Battista Bonfioli, Marianna Adamo, Cristina Gussago, Carlo Mario Lombardi, Matteo Pagnesi, Gianluigi Savarese, Marco Metra, Claudia Specchia
Summary: In patients with HF, regardless of their LVEF and clinical status, the addition of SGLT2i to SOC showed a significant improvement in quality of life as early as at 3-month follow-up.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Cell & Tissue Engineering
Satsuki Yamada, Jozef Bartunek, Thomas J. Povsic, Gad Cotter, Beth A. Davison, Christopher Edwards, Atta Behfar, Marco Metra, Gerasimos S. Filippatos, Marc Vanderheyden, William Wijns, Andre Terzic
Summary: Patients with heart failure often experience limitations in daily activities and poor quality of life. This study found that cell therapy can significantly improve the health-related quality of life in heart failure patients, particularly in those with pre-existing advanced left ventricular enlargement.
STEM CELLS TRANSLATIONAL MEDICINE
(2023)